1228780-49-1

Basic information

• Product Name: Methyl 2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-ene-1-carboxylate
• Synonyms: Methyl 2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-ene-1-carboxylate;methyl 4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-carboxylate
• CAS NO: 1228780-49-1
• Molecular Formula: C₁₆H₁₉ClO₂
• Molecular Weight: 278.77386
• Mol File: 1228780-49-1.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 357.8±42.0 °C(Predicted)
• Appearance: /
• Density: 1.124±0.06 g/cm3(Predicted)
• CAS DataBase Reference: Methyl 2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-ene-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-ene-1-carboxylate(1228780-49-1)
• EPA Substance Registry System: Methyl 2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-ene-1-carboxylate(1228780-49-1)

Safety Data

• Hazardous Substances Data: 1228780-49-1(Hazardous Substances Data)

Usage

Uses

Methyl 2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-ene-1-carboxylate is an intermediate in preparation of N-(phenylsulfonyl)benzamides and N-(3-pyridylsulfonyl)benzamides as anti-apoptotic Bcl 2 protein inhibitors and apoptosis-inducing agents for treatment of cancer, immune diseases, and autoimmune diseases.

Upstream product

• 1228780-46-8 methyl 4,4-dimethyl-2-(((trifluoromethyl)sulfonyl)oxy)cyclohex-1-ene-1-carboxylate 
• 1679-18-1 4-Chlorophenylboronic acid 
• 106-39-8 bromochlorobenzene 
• 32767-46-7 methyl 4,4-dimethyl-2-oxocyclohexancarboxylate 
• 637-87-6 1-Chloro-4-iodobenzene 
• 195062-61-4 4-chlorophenylboronic acid pinacol ester 
• 2979-19-3 3,3-dimethylcyclohexanone 

Downstream Products

• 1228780-51-5 (4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methanol 
• 1228780-71-9 tert-butyl 4-((4′-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1′-biphenyl]-2-yl)methyl)piperazine-1-carboxylate 
• 1228780-72-0 1-((4’-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1‘-biphenyl]-2-yl)methyl)piperazine 
• 1235865-76-5 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4’-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1’-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoic acid methyl ester 
• 1235865-77-6 [2-((1H-pyrrolo [2,3-b]pyridin-5-yl)oxy)-4-(4-((4’-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1’-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoic acid] 
• 1257044-40-8 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide 

Relevant articles and documents

Preparation method of Varonide Keebeck key intermediate

The invention discloses a preparation method of a venetoclax key intermediate, belonging to the technical field of pharmaceutical synthesis. The method comprises the steps of enabling deprotonated 3,3'-dimethylcyclohexanone to react with dimethyl carbonat

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Sulfonamide derivative and application thereof in pharmacy

The invention relates to a sulfonamide derivative and a pharmaceutical composition containing the same, and an application of the sulfonamide derivative and the pharmaceutical composition of the sulfonamide derivative in drug preparation, specifically the application in drug preparation of a BCL-2 family protein antagonist and the application in treatment of cancers.